11 research outputs found
Population pharmacokinetics of amikacin in neonatal intensive care unit patients
Background Amikacin treatment requires close monitoring of blood concentrations to increase the probability that levels achieved are both effective and safe. Aims We described population pharmacokinetics parameters of amikacin in newborns from a Neonatal Intensive Care Unit with suspected or documented sepsis. Methods A nonlinear mixed-effect model approach was used to analyse the data. Results Twenty seven neonates were enrolled. Final parameter estimates were: Ke(h-1)=0.232x(CR) Exp-0.85; V(mL/kg)=497. Conclusion Weight and serum creatinine are associated with neonatal amikacin volume of distribution and elimination constant rate, respectively. The presence of sepsis may decrease amikacin elimination, although this observation should be further explored. These results could help to individualize amikacin dosage for neonates
Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients
Tacrolimus is the cornerstone in pediatric liver transplant immunosuppression. Despite close monitoring, fluctuations in tacrolimus blood levels affect safety and efficacy of immunosuppressive treatments. Identifying the factors related to the variability in tacrolimus exposure may be helpful in tailoring the dose. The aim of the present study was to characterize the clinical, pharmacological, and genetic variables associated with systemic tacrolimus exposure in pediatric liver transplant patients. De novo transplant patients with a survival of more than 1 month were considered for inclusion and were genotyped for cytochrome P450 3A5 (CYP3A5). Peritransplant clinical factors and laboratory covariates were recorded retrospectively between 1 month and 2 years after transplant, including alanine aminotransferase (ALT), aspartate aminotransferase, hematocrit, and tacrolimus predose steady-state blood concentrations collected 12 hours after tacrolimus dosing. A linear mixed effect (LME) model was used to assess the association of these factors and the log-transformed tacrolimus dose-normalized trough concentration (logC0/D) levels. Bootstrapping was used to internally validate the final model. External validation was performed in an independent group of patients who matched the original population. The developed LME model described that logC0/D increases with increases in time after transplant (β = 0.019, 95% confidence interval [CI], 0.010-0.028) and ALT values (β = 0.00030, 95% CI, 0.00002-0.00056), whereas logC0/D is significantly lower in graft CYP3A5 expressers compared with nonexpressers (β = −0.349, 95% CI, −0.631 to −0.062). In conclusion, donor CYP3A5 genotype, time after transplant, and ALT values are associated with tacrolimus disposition between 1 month and 2 years after transplant. A better understanding of tacrolimus exposure is essential to minimize the occurrence of an out-of-range therapeutic window that may lead to adverse drug reactions or acute rejection.Fil: Riva, Natalia. Consejo Nacional de Investigaciones CientÃficas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Woillard, Jean Baptiste. Inserm; FranciaFil: Distefano, Maximiliano. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Moragas, MatÃas. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones CientÃficas y Técnicas; ArgentinaFil: Dip, Marcelo Fabian. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Halac, Esteban Tomas. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Cáceres Guido, Paulo. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Licciardone, Nieves. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Mangano, Andrea MarÃa Mercedes. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones CientÃficas y Técnicas; ArgentinaFil: Bosaleh, Andrea. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: de Davila, MarÃa Teresa. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Schaiquevich, Paula Susana. Consejo Nacional de Investigaciones CientÃficas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Imventarza, Oscar Cesar. Consejo Nacional de Investigaciones CientÃficas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentin
Therapeutic monitoring of pediatric transplant patients with conversion to generic tacrolimus
p>Objective: Therapeutic monitoring during interchange of tacrolimus commercial formulations is essential to ensure similar exposure in transplant patients. However, there are limited data in the pediatric transplant population. This study aims to evaluate exposure, safety and efficacy in maintenance pediatric transplant patients under generic tacrolimus substitution.
Method: Pediatric patients who underwent interchange of tacrolimus formulations were detected by the Service of Pharmacy and included in this study. Tacrolimus trough levels (C0), laboratory parameters and clinical characteristics were recorded before and after the switch. Statistical analysis was performed using Wilcoxon matched pair t-test.
Results: In total, 10 patients with kidney, liver, heart and hematopoietic stem cell transplantation received the innovator and switched to the generic product. The median (range) of the C0 normalized by the dose before and after switch was 74.8 [(ng/ml)/(mg/kg)] (13.8-518.4) and 65.1 [(ng/ml)/(mg/kg)] (13.5-723.5), respectively (p>0.05). Tacrolimus dose was 0.070(mg/kg) (0.024-0.461) and 0.069(mg/kg) (0.017- 0.571) for the innovator and generic formulation, respectively, with no difference when comparing both values (p>0.05). Laboratory parameters did not change after conversion (p>0.05). Adverse events, acute rejection, death and graft loss were not observed.
Conclusion: In our study population, no significant differences in terms of laboratory parameters, drug exposure and dose were observed. We emphasize the need of close monitoring to ensure a safe interchange, especially in vulnerable populations such as the pediatric. </p
Population pharmacokinetics of amikacin in neonatal intensive care unit patients
BackgroundAmikacin treatment requires close monitoring of blood concentrations to increase the probability that levels achieved are both effective and safe.AimsWe described population pharmacokinetics parameters of amikacin in newborns from a Neonatal Intensive Care Unit with suspected or documented sepsis.Methods A nonlinear mixed-effect model approach was used to analyse the data.Results Twenty seven neonates were enrolled. Final parameter estimates were: Ke(h-1)=0.232x(CR) Exp-0.85; V(mL/kg)=497.ConclusionWeight and serum creatinine are associated with neonatal amikacin volume of distribution and elimination constant rate, respectively. The presence of sepsis may decrease amikacin elimination, although this observation should be further explored. These results could help to individualize amikacin dosage for neonates
Population pharmacokinetics of amikacin in neonatal intensive care unit patients
Background
Amikacin treatment requires close monitoring of blood concentrations to increase the probability that levels achieved are both effective and safe.
Aims
We described population pharmacokinetics parameters of amikacin in newborns from a Neonatal Intensive Care Unit with suspected or documented sepsis.
Methods
A nonlinear mixed-effect model approach was used to analyse the data.
Results
Twenty seven neonates were enrolled. Final parameter estimates were: Ke(h-1)=0.232x(CR) Exp-0.85; V(mL/kg)=497.
Conclusion
Weight and serum creatinine are associated with neonatal amikacin volume of distribution and elimination constant rate, respectively. The presence of sepsis may decrease amikacin elimination, although this observation should be further explored. These results could help to individualize amikacin dosage for neonates
Adequate exposure to tacrolimus with sublingual administration in pediatric liver transplant patients
Fil: Riva, Natalia. Consejo Nacional de Investigaciones CientÃficas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Galván, MarÃa E.. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Caceres Guido, Paulo Arturo. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Dip, Marcelo. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Licciardone, Nieves. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Imventarza, Oscar. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Schaiquevich, Paula Susana. Consejo Nacional de Investigaciones CientÃficas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Buamscha, Daniel. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentin
Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis
Introduction: Amikacin is commonly used in patients with pediatric cystic fibrosis (CF) for the treatment of pulmonary exacerbations. Amikacin efficacy is related to maximum plasma concentration/minimum inhibitory concentration (Cmax/MIC) ratio >8. Pharmacokinetic data in patients with pediatric CF are scarce. The aim of this study was to develop a population pharmacokinetic (PopPK) model describing amikacin disposition in patients with pediatric CF. Methods: CF patients under 18 years of age with pulmonary exacerbation who received amikacin were enrolled. Patients received different amikacin regimens (30 mg−1 kg−1 day−1 every 8, 12, or 24 hours) depending on the patient's status and hospital protocols. Amikacin serum levels were obtained for therapeutic drug monitoring. PopPK model was developed using MONOLIX Suite-2018R1 (Lixoft). Results: A total of 39 patients (114 amikacin concentrations) were included in this study. Population estimates for the elimination rate constant (k) and the volume of distribution (V) were 0.541 hours−1 and 0.451 L/kg, respectively. Between-subject and between-occasion variability were 53% and 16.5% for k and 31% and 22% for V, respectively. Bodyweight was a significant covariate associated with V. Based on simulations, almost 70% of the patients receiving 30 mg−1 kg−1 day−1 every 24 hours would achieve a Cmax/MIC ratio >8 which is an appropriate therapeutic goal while no patient in the other two groups (Q8 and Q12) would achieve that objective. Conclusions: The regimen of 30 mg−1 kg−1 day−1 every 24 hours more adequately fulfilled the therapeutic target for amikacin. Although all our patients had good clinical results and a good adverse-events profile, further studies are necessary to redefine the optimal treatment strategy.Fil: Caceres Guido, Paulo Arturo. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Perez, Mariel. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Halac, Alicia. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Ferrari, Mariela. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Ibarra, Manuel. Universidad de la República; UruguayFil: Licciardone, Nieves. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Castaños, Claudio. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Gravina, Luis P.. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Jimenez, Cristina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Garcia Bournissen, Facundo. Gobierno de la Ciudad de Buenos Aires. Instituto Multidisciplinario de Investigaciones en PatologÃas Pediátricas. Consejo Nacional de Investigaciones CientÃficas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto Multidisciplinario de Investigaciones en PatologÃas Pediátricas; ArgentinaFil: Schaiquevich, Paula Susana. Consejo Nacional de Investigaciones CientÃficas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentin
Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis
Introduction: Amikacin is commonly used in patients with pediatric cystic fibrosis (CF) for the treatment of pulmonary exacerbations. Amikacin efficacy is related to maximum plasma concentration/minimum inhibitory concentration (Cmax/MIC) ratio >8. Pharmacokinetic data in patients with pediatric CF are scarce. The aim of this study was to develop a population pharmacokinetic (PopPK) model describing amikacin disposition in patients with pediatric CF. Methods: CF patients under 18 years of age with pulmonary exacerbation who received amikacin were enrolled. Patients received different amikacin regimens (30 mg−1 kg−1 day−1 every 8, 12, or 24 hours) depending on the patient's status and hospital protocols. Amikacin serum levels were obtained for therapeutic drug monitoring. PopPK model was developed using MONOLIX Suite-2018R1 (Lixoft). Results: A total of 39 patients (114 amikacin concentrations) were included in this study. Population estimates for the elimination rate constant (k) and the volume of distribution (V) were 0.541 hours−1 and 0.451 L/kg, respectively. Between-subject and between-occasion variability were 53% and 16.5% for k and 31% and 22% for V, respectively. Bodyweight was a significant covariate associated with V. Based on simulations, almost 70% of the patients receiving 30 mg−1 kg−1 day−1 every 24 hours would achieve a Cmax/MIC ratio >8 which is an appropriate therapeutic goal while no patient in the other two groups (Q8 and Q12) would achieve that objective. Conclusions: The regimen of 30 mg−1 kg−1 day−1 every 24 hours more adequately fulfilled the therapeutic target for amikacin. Although all our patients had good clinical results and a good adverse-events profile, further studies are necessary to redefine the optimal treatment strategy.Fil: Caceres Guido, Paulo Arturo. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Perez, Mariel. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Halac, Alicia. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Ferrari, Mariela. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Ibarra, Manuel. Universidad de la República; UruguayFil: Licciardone, Nieves. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Castaños, Claudio. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Gravina, Luis P.. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Jimenez, Cristina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Garcia Bournissen, Facundo. Gobierno de la Ciudad de Buenos Aires. Instituto Multidisciplinario de Investigaciones en PatologÃas Pediátricas. Consejo Nacional de Investigaciones CientÃficas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto Multidisciplinario de Investigaciones en PatologÃas Pediátricas; ArgentinaFil: Schaiquevich, Paula Susana. Consejo Nacional de Investigaciones CientÃficas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentin
Meropenen inhibits the cytochrome P450 (CYP) 3A-dependent biotransformation of the immunosuppressive tacrolimus in human liver microsomes
Tacrolimus (TAC), a immunosuppressive drug used in solid organ transplantation, is metabolized by CYP3A4 and 3A5. The simultaneous administration of TAC and meropenem (MEP) in pediatric kidney transplant patients may led to a significant increase in plasma concentrations of TAC. We hypothesized that this negative pharmacokinetic interaction is due to the inhibition of the CYP3A4-mediated biotransformation of TAC by MEP, particularly in those individuals lacking the expression of CYP3A5. The aim of this study was to evaluate in vitro the potential metabolic interaction between TAC and MEP. Human liver microsomes were prepared with discard liver samples obtained from healthy donors (n=2) and individuals subjected to tumor resection (n=2). The specific CYP3A-dependent enzyme activity, testosterone 6-beta hydroxylase, was assayed in the absence (control) and in presence of TAC (5 and 20 µM), MEP (10 µM) and the combinations of TAC and MEP. TAC, incubated at 5 and 20 µM, inhibited (p<0.05) the CYP3A-mediated 6-beta hydroxylation of testosterone (18±13% and 51±16%, respectively). This finding may confirm the high affinity of CYP3A4 for TAC. MEP, at 10 µM, did not affect this enzyme reaction. After co-incubations of TAC and MEP, testosterone 6-beta hydroxylase activities resembled those observed when TAC was incubated alone. In control assays, rates of TAC metabolism were 30±20 and 120±40 pmol/min.mg of microsomal protein, respectively. MEP, at 10 µM, significantly inhibited (p<0.05) the hepatic biotransformation of TAC; rates (pmol/min.mg) of TAC metabolism (at 5 and 20 µM) were 20±10 (43±24% inhibition) and 70±50 (49±23% inhibition), respectively. These preliminary results show a metabolic interaction between TAC and MRP on CYP3A-dependent metabolism in human liver. The enhancement of the systemic availability of TAC observed in vivo in the co-administration with MEP would be due to the inhibition of the CYP3A4-dependent biotransformation of the immunosuppressive drug.Fil: Riva, Natalia. Consejo Nacional de Investigaciones CientÃficas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Molina, Manuel. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Larsen, Karen Elizabeth. Consejo Nacional de Investigaciones CientÃficas y Técnicas. Centro CientÃfico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones CientÃficas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Trezeguet Renatti, Guido. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones CientÃficas y Técnicas; ArgentinaFil: Caceres Guido, Paulo Arturo. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Bressan, Ignacio Guillermo. Hospital Italiano; ArgentinaFil: Licciardone, Nieves. Hospital Italiano; ArgentinaFil: Monteverde, Marta. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Schaiquevich, Paula Susana. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones CientÃficas y Técnicas; ArgentinaFil: Virkel, Guillermo Leon. Consejo Nacional de Investigaciones CientÃficas y Técnicas. Centro CientÃfico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones CientÃficas. Centro de Investigación Veterinaria de Tandil; ArgentinaLXVI Reunión anual de la Sociedad Argentina de Investigación ClÃnica; LXIX Reunión anual de la Sociedad Argentina de ImmunologÃa; LIII Reunión anual de la Asociación Argentina de FarmacologÃa Experimental y XI Reunión anual de la Asociación Argentina de NanomedicinasArgentinaSociedad Argentina de Investigación ClÃnicaSociedad Argentina de InmunologÃaAsociación Argentina de FarmacologÃa ExperimentalAsociación Argentina de Nanomedicina
Survival time to biopsy-proven acute rejection and tacrolimus adverse drug reactions in pediatric liver transplantation
Background: Despite advances in surgical procedures and the optimization of immunosuppressive therapies in pediatric liver transplantation, acute rejection (AR) and serious adverse drug reaction (ADR) to tacrolimus still contribute to morbidity and mortality. Identifying risk factors of safety and efficacy parameters may help in optimizing individual immunosuppressive therapies. This study aimed to identify peritransplant predictors of AR and factors related to the risk of ADR to tacrolimus in a large Latin American cohort of pediatric liver transplant patients. Methods: We performed a retrospective cohort study in a pediatric liver transplant population (n = 72). Peritransplant variables were collected retrospectively including demographic, clinical, laboratory parameters, genomic (CYP3A5 donor and recipients polymorphism), and tacrolimus trough concentrations (C0) over a 2-year follow-up period. Variability in tacrolimus C0 was calculated using percent coefficient of variation and tortuosity. ADR- and AR-free survival rates were calculated using the Kaplan–Meier method, and risk factors were identified by multivariate Cox regression models. Results: Cox-proportional hazard models identified that high tortuosity in tacrolimus C0 was associated with an 80% increased risk of AR [hazard ratio (HR), 1.80; 95% confidence interval (CI), 1.01–3.22; P, 0.05], whereas steroid in maintenance doses decreased this risk (HR, 0.56; 95% CI, 0.31–0.99; P, 0.05). Forty-six patients experienced at least one ADR including hypomagnesemia, nephrotoxicity, hypertension, malignancies, and tremor as a first event. Multivariate analysis showed that C0 values 10 days before the event (HR, 1.25; 95% CI, 1.21–1.39; P, 0.0001) and CYP3A5 expresser recipients (HR, 2.05; 95% CI, 1.03–4.06; P, 0.05) were independent predictors of ADR. Conclusions: Tacrolimus C0 values, its variability, and CYP3A5 polymorphisms were identified as risk factors of AR and tacrolimus ADR. This knowledge may help to control and reduce their incidence in pediatric liver transplant patients. Prospective studies are important to validate these results.Fil: Riva, Natalia. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones CientÃficas y Técnicas; ArgentinaFil: Dip, Marcelo. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Halac, Esteban. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Guido, Paulo Cáceres. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Woillard, Jean B.. No especifÃca;Fil: Licciardone, Nieves. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Chan, Debora. Universidad Tecnológica Nacional; ArgentinaFil: BuendÃa, Jefferson. Universidad de Buenos Aires; ArgentinaFil: Borgnia, Daniela. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Bosaleh, Andrea. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: de Davila, MarÃa T.. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; ArgentinaFil: Imventarza, Oscar Cesar. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones CientÃficas y Técnicas; ArgentinaFil: Schaiquevich, Paula Susana. Consejo Nacional de Investigaciones CientÃficas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de PediatrÃa "Juan P. Garrahan"; Argentin